2017
DOI: 10.1016/j.ejphar.2017.05.017
|View full text |Cite
|
Sign up to set email alerts
|

Anhydroicaritin, a SREBPs inhibitor, inhibits RANKL-induced osteoclastic differentiation and improves diabetic osteoporosis in STZ-induced mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
14
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 29 publications
(16 citation statements)
references
References 37 publications
0
14
0
Order By: Relevance
“…Consequently, SREBPs regulate cellular lipogenesis and lipid homeostasis [11]. SREBPs are divided into three isoforms: SREBP-1a, SREBP-1c, and SREBP2 [12]. SREBP-1 mainly controls the gene expression involved in fatty acid and triacylglycerol metabolism, while SREBP-2 regulates primarily cholesterol metabolism [13].…”
Section: Introductionmentioning
confidence: 99%
“…Consequently, SREBPs regulate cellular lipogenesis and lipid homeostasis [11]. SREBPs are divided into three isoforms: SREBP-1a, SREBP-1c, and SREBP2 [12]. SREBP-1 mainly controls the gene expression involved in fatty acid and triacylglycerol metabolism, while SREBP-2 regulates primarily cholesterol metabolism [13].…”
Section: Introductionmentioning
confidence: 99%
“…Anhydroicaritin is a prenylated flavonoid found in several species of Epimedium . Anhydroicaritin is capable of suppressing osteoclast differentiation and improving bone loss in diabetic rats (12).…”
Section: Introductionmentioning
confidence: 99%
“…RANKL stimulates osteoclastic activity and differentiation and inhibits osteoclast apoptosis. OPG inhibits osteoclast formation by binding to RANKL [ 22 ]. The bone remodeling process is dependent on the balance of these two proteins, while a low ratio of OPG/RANKL characterizes the increased osteolytic process.…”
Section: Introductionmentioning
confidence: 99%